KGA-2727

KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat) . KGA-2727 has antidiabetic efficacy[1].

Product Specifications

CAS Number

[666842-36-0]

UNSPSC

12352005

Hazard Statement

H302, H319

Target

SGLT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/kga-2727.html

Purity

98.84

Solubility

DMSO : 200 mg/mL (ultrasonic) |Ethanol : 100 mg/mL (ultrasonic) |H2O : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N)CCNCCCOC1=CC=C(CC2=C(C(C)C)NN=C2O[C@H]3[C@@H]([C@H]([C@@H]([C@@H](CO)O3)O)O)O)C(C)=C1

Molecular Formula

C26H40N4O8

Molecular Weight

536.62

Precautions

H302, H319

References & Citations

[1]Shibazaki T, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2012 Aug;342 (2) :288-96.